__NUXT_JSONP__("/drugs/Emibetuzumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1365287-97-3",chebiId:b,chemicalFormula:b,definition:"A humanized IgG4 monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-MET) with potential antineoplastic activity. Emibetuzumab binds to c-MET, thereby preventing the binding of HGF to its receptor c-Met and subsequent activation of the HGF\u002Fc-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.",fdaUniiCode:"MO4K3GDN1I",identifier:"C95732",preferredName:a,semanticType:"Immunologic Factor",subclassOf:["C129822","C164001"],synonyms:["Anti-c-MET Monoclonal Antibody LY2875358","EMIBETUZUMAB",a,"LA-480","LY2875358"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FEmibetuzumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Emibetuzumab","","2021-10-30T13:48:08.333Z")));